Search Results - "Tonkin, K"

Effectiveness of physician-targeted interventions to improve antibiotic use for respiratory tract infections by van der Velden, Alike W, Pijpers, Eefje J, Kuyvenhoven, Marijke M, Tonkin-Crine, Sarah K G, Little, Paul, Verheij, Theo J M

“…Antibiotic use and concomitant resistance are increasing. Literature reviews do not unambiguously indicate which interventions are most effective in improving…”
Get full text

Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival by SINGHAL, H, BAUTISTA, D. S, TONKIN, K. S, O'MALLEY, F. P, TUCK, A. B, CHAMBERS, A. F, HARRIS, J. F

“…Osteopontin (OPN) is a secreted, integrin-binding phosphoprotein that has been implicated in both normal and pathological processes; qualitative increases in…”
Get full text

A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12) by Bramwell, V.H.C., Pritchard, K.I., Tu, D., Tonkin, K., Vachhrajani, H., Vandenberg, T.A., Robert, J., Arnold, A., O'Reilly, S.E., Graham, B., Shepherd, L.

“…In the early 1990s, the role of adjuvant tamoxifen in premenopausal women with early breast cancer (EBC) was not established. Similarly, optimum timing…”
Get full text

Osteopontin expression in a group of lymph node negative breast cancer patients by Tuck, Alan B., O'Malley, Frances P., Singhal, Hemant, Harris, John F., Tonkin, Katia S., Kerkvliet, Nancy, Saad, Zahida, Doig, Gordon S., Chambers, Ann F.

“…The aim of this study was to examine the cellular distribution of osteopontin (OPN) protein [by immunohistochemical (IHC) analysis] and mRNA [by in situ…”
Get full text

Phase II Study of Docetaxel, Doxorubicin, and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer by NABHOLTZ, J. M, MACKEY, J. R, SMYLIE, M, PATERSON, A, NOËL, D. R, AL-TWEIGERI, T, TONKIN, K, NORTH, S, AZLI, N, RIVA, A

“…This pilot phase II study investigated the efficacy and toxicity of docetaxel with doxorubicin and cyclophosphamide (TAC) as first-line chemotherapy for…”
Get full text

AOSOP6 Results from the 2-year open-label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab by Stopeck, A.T, Lipton, A, Martín, M, Body, J-J, Paterson, A, Steger, G.G, Tonkin, K, de Boer, R.H, Fujiwara, Y, Yardley, D, Jassem, J, Takano, T, Solal-Céligny, P, Fan, M, Braun, A

“…Background Denosumab was superior to zoledronic acid (ZA) in reducing the risk of a first on-study skeletal-related event (SRE; HR, 0.82; 95% confidence…”
Get full text

The malignant wound assessment tool: a validation study using a Delphi approach by Schulz, V, Kozell, K, Biondo, PD, Stiles, C, Tonkin, K, Hagen, NA

“…Malignant wounds, caused by the direct invasion of cancer into the skin, occur in cancer patients with primary skin tumours and as cutaneous metastasis in…”
Get full text

Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective by Oza, A M, Castonguay, V, Tsoref, D, Diaz-Padilla, I, Karakasis, K, Mackay, H, Welch, S, Weberpals, J, Hoskins, P, Plante, M, Provencher, D, Tonkin, K, Covens, A, Ghatage, P, Gregoire, J, Hirte, H, Miller, D, Rosen, B, Maroun, J, Buyse, M, Coens, C, Brady, M F, Stuart, G C E

“…Ovarian cancer is leading cause of gynecologic cancer mortality in Canada. To date, overall survival (os) has been the most-used endpoint in oncology trials…”
Get full text

Association of Academic Physiatrists Residency and Fellowship Program Directors' Resident Recruitment Subcouncil Position Paper on Residency Recruitment by Dragojlovic, Nikola, Romanoski, Natasha L, Bolger, Ashlee, Friedlander, Tracy, Helkowski, Wendy, Huss, Sara A, Jenkins, Jeffrey G, Knowlton, Tiffany, Nguyen, Dianna H, Rand, Stephanie E, Raum, George, Sullivan, William, Tonkin, Brionn K, Escalon, Miguel X

“…Residency recruitment practices have undergone significant changes in the last several years. Interviews are now conducted fully virtually leading to both…”
Get full text

A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes by Findlay, B., Tonkin, K., Crump, M., Norris, B., Trudeau, M., Blackstein, M., Burnell, M., Skillings, J., Bowman, D., Walde, D., Levine, M., Pritchard, K. I., Palmer, M. J., Tu, D., Shepherd, L.

“…Background: Dose-dense and dose-intensive regimens have improved the outcome of breast cancer in high-risk women with operable disease. Patients and methods:…”
Get full text

Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer by Nabholtz, J M, North, S, Smylie, M, Mackey, J, Au, H J, Au, R, Morrish, D, Salter, E, Tonkin, K

“…Considering the single-agent activity of docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) and doxorubicin in breast cancer and their potential…”
Get more information

Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting by Nabholtz, J M, Tonkin, K, Smylie, M, Mackey, J, Janowska-Wieczorek, A

“…Considering the efficacy of docetaxel (Taxotere, Rhône-Poulenc Rorer, Antony, France) and doxorubicin in advanced breast cancer and their potential…”
Get more information

Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer by Nabholtz, J M, Mackey, J, Smylie, M, Tonkin, K

“…Considering the recommended dose of the docetaxel/doxorubicin combination (75 mg/m2 and 50 mg/m2, respectively), we decided to proceed with a pilot program in…”
Get more information

Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32 by Goodwin, Pamela J, Parulekar, Wendy R, Gelmon, Karen A, Shepherd, Lois E, Ligibel, Jennifer A, Hershman, Dawn L, Rastogi, Priya, Mayer, Ingrid A, Hobday, Timothy J, Lemieux, Julie, Thompson, Alastair M, Pritchard, Kathleen I, Whelan, Timothy J, Mukherjee, Som D, Chalchal, Haji I, Oja, Conrad D, Tonkin, Katia S, Bernstein, Vanessa, Chen, Bingshu E, Stambolic, Vuk

“…Metformin may improve metabolic factors (insulin, glucose, leptin, highly sensitive C-reactive protein [hs-CRP]) associated with poor breast cancer outcomes…”
Get full text

Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas by Tuck, A B, O'Malley, F P, Singhal, H, Tonkin, K S, Harris, J F, Bautista, D, Chambers, A F

“…To examine the association between expression of osteopontin (OPN), p53, other molecular markers (Ki-67, c-erb B2, and estrogen receptor protein) and tumor…”
Get more information

Docetaxel and anthracycline polychemotherapy in the treatment of breast cancer by Nabholtz, J M, Smylie, M, Mackey, J, Au, H J, Tonkin, K, Au, R, Morrish, D, Salter, E

“…Given the single-agent activity of docetaxel and doxorubicin in metastatic breast cancer and their potential non-cross-resistance, several phase I/II pilot…”
Get more information

High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines by STUART, N. S. A, PHILIP, P, HARRIS, A. L, TONKIN, K, HOULBROOK, S, KIRK, J, LIEN, E. A, CARMICHAEL, J

“…Twenty-six patients with relapsed or drug-resistant cancer were treated with a combination of oral etoposide (300 mg day-1 for 3 days) and high-dose oral…”
Get full text

Carboplatin hypersensitivity: case reports and review of the literature by Tonkin, K S, Rubin, P, Levin, L

Get more information

Neoadjuvant Therapy for Breast Cancer: Updates and Proceedings From the Seventh Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer by Arnaout, A., Lee, J., Gelmon, K., Poirier, B., Lu, F.I., Akra, M., Boileau, J.F., Tonkin, K., Li, H., Illman, C., Simmons, C., Grenier, D.

“…Therapy for breast cancer involves a complex interplay of three main treatment modalities: surgery, systemic therapy, and radiation therapy. The Canadian…”
Get full text

A Randomized Trial of Paracentesis plus Intraperitoneal Tumor Necrosis Factor-α versus Paracentesis Alone in Patients with Symptomatic Ascites from Recurrent Ovarian Carcinoma by Hirte, H.W., Miller, D., Tonkin, K., Findlay, B., Capstick, V., Murphy, J., Buckman, R., Carmichael, J., Levine, M., Hill, W.

“…Purpose: Previous phase I and II studies of intraperitoneal recombinant human tumor necrosis factor-α (rhTNF-α) suggested a high degree of efficacy in reducing…”
Get full text